

A Randomized Open-label Phase 2 Study of TALazoparib with or without ENZaluTamide in Patients with Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate (TALENT)

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes involved in homologous recombination repair (HRR) - cancer has progressed despite prior hormone-based treatment and shows ongoing disease activity - ability to perform most daily activities - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- prior treatment with certain prostate cancer therapies (such as PARP inhibitors or specific chemotherapy/targeted drugs) - serious or uncontrolled medical conditions that could affect safety (such as uncontrolled heart disease, seizures, or brain/spinal metastases) - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Interventions:

Drug: Talazoparib, Drug: Talazoparib with enzalutamide

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), mCRPC, Metastatic castration-resistant prostate cancer

More Information

Description: The purpose of this study is to find out whether a study drug called talazoparib, given alone or in combination with enzalutamide, can help slow down or delay the growth of prostate cancer in people whose cancer has spread and no longer responds to hormone therapy. This study includes people whose cancer has specific genetic changes and who have previously been treated with another prostate cancer medicine called abiraterone acetate.

Study Contact: Ian Okazaki - okaza001@umn.edu

Principal Investigator: Ian Okazaki

Phase: PHASE2

IRB Number: STUDY00026000

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.